Archives

LLS, Dana-Farber partner to bring clinical trials to local communities

Friday, June 7, 2013 01:29 PM

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency, joined the Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of blood cancer therapies in community oncology settings across the country.

More... »

Neurelis, Biotie Therapies partners, with acquisition option

Thursday, June 6, 2013 01:46 PM

Pharmaceutical company Neurelis has signed an agreement with Biotie Therapies, a specialized drug development company, to develop intranasal diazepam (NRL-1) and provide Biotie with the exclusive option, but not the obligation, to acquire all outstanding shares of Neurelis.

More... »

MorphoSys, GSK ink license agreement

Thursday, June 6, 2013 01:35 PM

Pharmaceutical developer MorphoSys has entered into a global agreement with GlaxoSmithKline to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody against GM-CSF, which has concluded phase I/II development in mild to moderate rheumatoid arthritis.

More... »

Pfizer, UCSF partner to expand drug discovery capabilities

Thursday, June 6, 2013 10:22 AM

Pfizer has expanded its Centers for Therapeutic Innovation (CTI), which is dedicated to establishing partnerships with academic medical centers, into the development of small-molecule drug candidates through a partnership with the University of California, San Francisco (UCSF). This partnership provides investigators from UCSF with access to Pfizer's small-molecule drug development capabilities, working with Pfizer scientists with the goal of jointly translating basic research into drug candidates to bring new therapies to patients.

More... »

Maxygen board to dissolve, liquidate company

Wednesday, June 5, 2013 01:42 PM

The board of biopharmaceutical company Maxygen has approved the liquidation and dissolution of the company, subject to shareholder approval, and plans to distribute all available cash to its shareholders after making reasonable provision for known and potential liabilities and other obligations of the company. Maxygen currently estimates the initial liquidating distribution to stockholders will be between $68.2 million and $69.6 million, or $2.45 to $2.50 per share.

More... »

MJFF launches $10 million programs for Parkinson’s research

Wednesday, June 5, 2013 01:40 PM

Michael J. Fox Foundation for Parkinson's Research (MJFF) has committed up to $10 million to its next funding round for the Edmond J. Safra Core Programs for PD research to prioritize research toward transformative treatments and a cure for Parkinson's disease (PD).

More... »

Fujifilm, Dr. Reddy's call off joint venture for generic drugs in Japan

Wednesday, June 5, 2013 01:37 PM

Healthcare company Fujifilm and India-based global pharmaceutical company Dr. Reddy's Laboratories have decided to terminate the Memorandum of Understanding (MoU) to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan.

More... »

Japan screening massive drug compound libraries for new treatments

Wednesday, June 5, 2013 01:32 PM

The Global Health Innovative Technology Fund (GHIT Fund), a public-private partnership focused on Japanese R&D related to infectious disease, will make a series of agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis and other afflictions.

More... »

Sanford-Burnham, Pfizer collaborate to speed drug discovery

Wednesday, June 5, 2013 01:18 PM

Sanford-Burnham Medical Research Institute has partnered with Pfizer as part of Pfizer's focus on translational medicine. The Centers for Therapeutic Innovation (CTI) is Pfizer’s research unit dedicated to establishing global partnerships with academic research institutions.

More... »

HealthCarePoint pledges $10 million in technology services to support ACRES

Tuesday, June 4, 2013 03:03 PM

HealthCarePoint (HCP), a Texas-based healthcare and clinical research networking technology corporation, is pledging more than $10 million in technologies and infrastructure services to ACRES, the Alliance for Clinical Research Excellence and Safety, a Cambridge-based nonprofit organization established to develop a global system for improving quality, safety, ethics and operational effectiveness in drug development and health research.

More... »